With the emergence of new and more infectious variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the induction of population immunity by mass vaccination appears to be the only definitive way to return to a ‘normal’ way of life. While some SARS-CoV-2 vaccines are already being distributed to millions of people under emergency use authorization, issues of stability and cost require the development of others.
A new bioRxiv* preprint describes the production of a new RNA vaccine delivery system that promises greater ease of storage and distribution. This could help boost vaccination rates in regions without adequate infrastructure for low-temperature storage.
